CSL Behring – Withdrawal of Hizentra® [immune globulin subcutaneous (human)]
On January 10, 2022 CSL Behring announced an expansion to a patient-level withdrawal, to include two additional lots of Hizentra [immune globulin subcutaneous (human)] due to an increased frequency of reports of injection-site reactions and local hypersensitivity-type of events after administration. This is an expansion to the withdrawal that was announced on December 30, 2021.
Top